Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q1 2022 · 10-Q
Revenue$17.26M$17.26M+17.5% vs Q1 2021 Net Income-$7.74M-$7.74MN/M vs Q1 2021 EPS Diluted-$0.11-$0.11N/M vs Q1 2021 Gross Profit$10,532,000+14.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flow-$7,198,000N/M Margins · derivedGross margin61.0%−1.9 pt vs Q1 2021
Operating margin-44.8%+5.3 pt vs Q1 2021
Net margin-44.8%+5.4 pt vs Q1 2021
ended Mar 31, 2022 · filed May 12, 2022 · 42 d after period end